Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... critically-ill and cardiac surgery patients in multiple countries ... results for the fiscal year ending December 31, ... were a record $3.1M, an increase of $2.3M ... $0.8M Highlights for the Year Ending December 31, ...
(Date:3/31/2015)... , March 31, 2015  Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Conway, Arkansas . The over 16,000 ... business on March 26 th 2015 and brings ... eighteen. "This facility represents another milestone ...
(Date:3/31/2015)... VANCOUVER , March 31, 2015  /PRNewswire/ ... announced today that it has filed with the Food ... New Drug ("IND") application related to the Company,s proposed ... of the IND application is required in order for ... US.  The IND application is a ...
(Date:3/31/2015)... 31, 2015 Eastern Kentucky University ... online bachelor’s of criminal justice degree programs by ... to inspiring ideas and high quality educational opportunities,” ... the University. We are confident that students will ... This is the site’s first “Students before Profits” ...
Breaking Biology Technology:CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... features an unprecedented use of fluorescent proteins to ... living organism. Dr. Hidehito Kuroyanagi and colleagues at ... transgenic alternative splicing reporter system to monitor the ... live C. elegans worms. , The splicing of let-2 ...
... In a significant step towards improving the design ... microfluidic lab-on-a-chip devices, researchers with the U.S. ... Lab) and the University of California (UC) at ... to the study of gas-phase reactions on the ...
... Nycomed has granted,Sepracor, Inc. (NASDAQ: ... rights for Ciclesonide in the United States. ... principle of action. It,is the active ingredient ... of asthma and in the Omnaris(TM) Nasal ...
Cached Biology Technology:Berkeley scientists bring MRI/NMR to microreactors 2Berkeley scientists bring MRI/NMR to microreactors 3Berkeley scientists bring MRI/NMR to microreactors 4Berkeley scientists bring MRI/NMR to microreactors 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Law Enforcement Data Sharing Consortium Now Includes over ... International, Inc. (OTC Bulletin Board: BKYI), a leader ... solutions, today announced a contract award from the ... law enforcement mobile data solution. Using MobileCop on ...
... LANSING, Mich. Michigan State University plant scientists have identified ... those findings led them to discover that the plants were ... smell, in a way that flies in the face of ... ways to protect plants from pests. Based on years ...
... 26--Researchers from around the world will present the ... of light waves at the 2009 Conference on ... 31 to June 5 at the Baltimore Convention ... THE MEETING: , Healing with Light, Vehicles ...
Cached Biology News:Tulsa County Sheriff Selects BIO-key(R) Mobile Data System 2MSU discoveries upend traditional thinking about how plants make certain compounds 2Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 2Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 3Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 4Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 5Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 6Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 7Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 8Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 9Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 10Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics 11
...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
...
Biology Products: